Core Insights - Calidi Biotherapeutics is presenting data on its innovative RedTail platform for targeted genetic medicines at the AACR Immuno-Oncology conference, focusing on its application in solid tumors [1][3] Group 1: RedTail Platform - The RedTail platform is designed for systemic delivery of virotherapy, targeting tumors and remodeling the tumor microenvironment (TME) to enhance therapeutic efficacy [2][5] - CLD-401, the lead candidate from the RedTail platform, is engineered to express high levels of IL-15 superagonist (IL-15 SA), which activates T-cells within the TME [2][6] Group 2: Clinical Development - Data presented indicates that RedTail can express both a functional BiTE and IL-15 SA, facilitating T-cell activation and TME alteration simultaneously, potentially overcoming previous limitations of BiTEs in solid tumors [3][4] - Calidi is conducting IND-enabling studies for CLD-401, targeting non-small cell lung cancer, head and neck cancer, and other high unmet medical need tumor types, with plans to submit an Investigational New Drug (IND) application by the end of 2026 [4][6] Group 3: Company Overview - Calidi Biotherapeutics is focused on developing targeted therapies that deliver genetic medicines to metastatic disease sites, utilizing an engineered enveloped oncolytic virus to shield from immune clearance [5][6] - The company is actively pursuing strategic partnerships to enhance clinical development and expand the impact of its RedTail platform [4]